Hypoxia preconditioning of mesenchymal stromal cells enhances PC3 cell lymphatic metastasis accompanied by VEGFR-3/CCR7 activation

Journal of Cellular Biochemistry

Volumn 114, Issue 12, 2013, Pages 2834-2841

  Huang, Xin ^a   Su, Kunkai ^b   Zhou, Limin ^c   Shen, Guofang ^c   Dong, Qi ^a   Lou, Yijia ^c   Zheng, Shu ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

CCR7; HYPOXIA PRECONDITIONING; LYMPHATIC METASTASIS; MESENCHYMAL STROMAL CELL; PROSTATE CANCER; VEGFR 3

Indexed keywords

CHEMOKINE RECEPTOR CCR7; I KAPPA B ALPHA; JANUS KINASE 1; JANUS KINASE 2; LENTIVIRUS VECTOR; PROTEIN KINASE B; SECONDARY LYMPHOID TISSUE CHEMOKINE; STAT3 PROTEIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; MESENCHYMAL STROMA CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

CCR7; HYPOXIA PRECONDITIONING; LYMPHATIC METASTASIS; MESENCHYMAL STROMAL CELL; PROSTATE CANCER; VEGFR-3;

ANIMALS; ANOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; HUMANS; LYMPHATIC METASTASIS; MALE; MESENCHYMAL STROMAL CELLS; MICE; PROSTATIC NEOPLASMS; RECEPTORS, CCR7; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885648162     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24629     Document Type: Article

References (26)

1. Baggiolini M,. 1998. Chemokines and leukocyte traffic. Nature 392: 565-568.
2. Baloǧlu E, Ke A, Abu-Taha I, Bärtsch P, Mairbäurl H,. 2009. In vitro hypoxia impairs β2-adrenergic receptor signaling in primary rat alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 296: L500-L509.
3. Chaudary N MM, Hill RP,. 2011. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia-induced lymph node metastases in cervix cancer. Gynecol Oncol 123: 393-400.
4. Cooper C, Chay C, Gendernalik J, Lee H, Bhatia J, Taichman R, McCauley L, Keller E, Pienta K,. 2003. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97 (3 Suppl): 739-747.
5. Denis L, Griffiths K,. 2000. Endocrine treatment in prostate cancer. Semin Surg Oncol 18: 52-74.
6. Dieu M, Vanbervliet B, Vicari A, Bridon J, Oldham E, Aït-Yahia S, Brière F, Zlotnik A, Lebecque S, Caux C,. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 373-386.
7. Heresi G, Wang J, Taichman R, Chirinos J, Regalado J, Lichtstein D, Rosenblatt J,. 2005. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: Report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 23: 261-267.
8. Hirakawa S, Brown L, Kodama S, Paavonen K, Alitalo K, Detmar M,. 2007. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109: 1010-1017.
9. Hirao M, Onai N, Hiroishi K, Watkins S, Matsushima K, Robbins P, Lotze M, Tahara H,. 2000. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60: 2209-2217.
10. Issa A LT, Shoushtari AN, Shields JD, Swartz MA,. 2009. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 69: 349-357.
11. Karnoub A, Dash A, Vo A, Sullivan A, Brooks M, Bell G, Richardson A, Polyak K, Tubo R, Weinberg R,. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
12. Kido A, Yoshitani K, Shimizu T, Akahane M, Fujii H, Tsukamoto S, Kondo Y, Honoki K, Imano M, Tanaka Y,. 2012. Effect of mesenchymal stem cells on hypoxia-induced desensitization of β2-adrenergic receptorsin rat osteosarcoma cells. Oncol Lett 4: 745-750.
13. Kuhn NZ, Tuan RS,. 2010. Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis. J Cell Physiol 222: 268-277.
14. Li R, Younes M, Wheeler T, Scardino P, Ohori M, Frolov A, Ayala G,. 2004. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 58: 193-199.
15. Liu FY ZZ, Li P, Ding X, Zong ZH, Sun CF,. 2010. Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 48: 291-296.
16. Ma M, Ye J, Deng R, Dee C, Chan G,. 2011. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer Lett 312: 1-10.
17. Mandriota S, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson D, Orci L, Alitalo K, Christofori G, Pepper M,. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682.
18. Murphy P, Baggiolini M, Charo I, Hébert C, Horuk R, Matsushima K, Miller L, Oppenheim J, Power C,. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
19. Olsson A, Dimberg A, Kreuger J, Claesson-Welsh L,. 2006. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
20. Park SJ, Shin EJ, Min SS, An J, Li Z, Hee Chung Y, Hoon Jeong J, Bach JH, Nah SY, Kim WK, Jang CG, Kim YS, Nabeshima YI, Nabeshima T, Kim HC,. 2013. Inactivation of JAK2/STAT3 signaling axis and downregulation of M1 mAChR cause cognitive impairment in klotho mutant mice, a genetic model of aging. Neuropsychopharmacology 38: 1426-1437. doi: 10.1038/npp.2013.39
21. Rattigan Y, Hsu J, Mishra P, Glod J, Banerjee D,. 2010. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp Cell Res 316: 3417-3424.
22. Sinha S VP, Bhattacharya R, Dutta S, Sinha S, Mukhopadhyay D,. 2009. Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2. J Cell Sci 122: 3385-3392.
23. Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, Imai T, Yoshie O, Bonecchi R, Mantovani A,. 1998. Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties. J Immunol 161: 1083-1086.
24. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova T, Kubo H, Thurston G, McDonald D, Achen M, Stacker S, Alitalo K,. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20: 1223-1231.
25. Zhong H, Semenza G, Simons J, De Marzo A,. 2004. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28: 88-93.
26. Zlotnik A, Yoshie O,. 2000. Chemokines: A new classification system and their role in immunity. Immunity 12: 121-127.